Mepolizumab in eosinophilic disorders

References

• American Lung Association, Epidemiology and Statistics Unit, Research Program Services Division. Trends in Asthma Morbidity and Mortality. Epidemiology and Statistics Program Trend Reports. American Lung Association, Washington DC, USA (2010).
   Google Scholar
• World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. Global Alliance against Respiratory Diseases, Bousquet J, Khaltaev N (Eds). WHO, Geneva, Switzerland (2007).
   Google Scholar
• Fox VL, Nurko S, Furuta GT. Eosinophilic esophagitis: it’s not just kid’s stuff. Gastrointest. Endosc.56(2), 260–270 (2002).
   PubMed Web of Science ®Google Scholar
• Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology125(6), 1660–1669 (2003).
   PubMed Web of Science ®Google Scholar
• Orenstein SR, Shalaby TM, Di LC et al. The spectrum of pediatric eosinophilic esophagitis beyond infancy: a clinical series of 30 children. Am. J. Gastroenterol.95(6), 1422–1430 (2000).
   PubMedGoogle Scholar
• Ferreira CT, Vieira MC, Vieira SM, da Silva GS, Yamamoto DR, da Silveira TR. Eosinophilic esophagitis in 29 pediatric patients. Arq. Gastroenterol.45(2), 141–146 (2008).
   PubMedGoogle Scholar
• Cheung KM, Oliver MR, Cameron DJ, Catto-Smith AG, Chow CW. Esophageal eosinophilia in children with dysphagia. J. Pediatr. Gastroenterol. Nutr.37(4), 498–503 (2003).
   PubMedGoogle Scholar
• Furuta GT, Liacouras CA, Collins MH et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology133(4), 1342–1363 (2007).
   PubMed Web of Science ®Google Scholar
• Konikoff MR, Noel RJ, Blanchard C et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology131(5), 1381–1391 (2006).
   PubMed Web of Science ®Google Scholar
• Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am. J. Gastroenterol.102(10), 2271–2279 (2007).
   PubMed Web of Science ®Google Scholar
• Zia-Amirhosseini P, Minthorn E, Benincosa LJ et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J. Pharmacol. Exp. Ther.291(3), 1060–1067 (1999).
   PubMed Web of Science ®Google Scholar
• Hart TK, Cook RM, Zia-Amirhosseini P et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J. Allergy Clin. Immunol.108(2), 250–257 (2001).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Withdrawal Assessment Report for Bosatria. European Medicines Agency, London, UK (2009).
   Google Scholar
• Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin. Pharmacokinet.50(4), 215–227 (2011).
   PubMed Web of Science ®Google Scholar
• Campbell HD, Tucker WQ, Hort Y et al. Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). Proc. Natl Acad. Sci. USA84(19), 6629–6633 (1987).
   PubMed Web of Science ®Google Scholar
• Minamitake Y, Kodama S, Katayama T, Adachi H, Tanaka S, Tsujimoto M. Structure of recombinant human interleukin 5 produced by Chinese hamster ovary cells. J. Biochem.107(2), 292–297 (1990).
   PubMed Web of Science ®Google Scholar
• Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood79(12), 3101–3109 (1992).
   PubMed Web of Science ®Google Scholar
• Milburn MV, Hassell AM, Lambert MH et al. A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature363(6425), 172–176 (1993).
   PubMed Web of Science ®Google Scholar
• Wells TN, Graber P, Proudfoot AE et al. The three-dimensional structure of human interleukin-5 at 2.4-angstroms resolution: implication for the structures of other cytokines. Ann. NY Acad. Sci.725, 118–127 (1994).
   PubMed Web of Science ®Google Scholar
• McKinnon M, Bank M, Solari R, Robinson G. Interleukin-5 and the interleukin receptor: targets for drug discovery in asthma. In: Interleukin-5: From Molecule to Drug Target for Asthma. Sanderson CJ (Ed.). Marcel Dekker, Inc., New York, 299–320 (1999).
   Google Scholar
• Menzies-Gow A, Flood-Page P, Sehmi R et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J. Allergy Clin. Immunol.111(4), 714–719 (2003).
   PubMed Web of Science ®Google Scholar
• Clutterbuck E, Shields JG, Gordon J et al. Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays. Eur. J. Immunol.17(12), 1743–1750 (1987).
   PubMed Web of Science ®Google Scholar
• Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J. Exp. Med.167(1), 219–224 (1988).
   PubMed Web of Science ®Google Scholar
• Ohnishi T, Sur S, Collins DS, Fish JE, Gleich GJ, Peters SP. Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge. J. Allergy Clin. Immunol.92(4), 607–615 (1993).
   PubMed Web of Science ®Google Scholar
• Clutterbuck EJ, Sanderson CJ. Regulation of human eosinophil precursor production by cytokines: a comparison of recombinant human interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6, and rh granulocyte-macrophage colony-stimulating factor. Blood75(9), 1774–1779 (1990).
   PubMed Web of Science ®Google Scholar
• Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med.183(1), 195–201 (1996).
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Cieslewicz G, Schwarze J et al. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med.160(3), 934–941 (1999).
   PubMed Web of Science ®Google Scholar
• Lee JJ, Dimina D, Macias MP et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science305(5691), 1773–1776 (2004).
   PubMed Web of Science ®Google Scholar
• Humbles AA, Lloyd CM, McMillan SJ et al. A critical role for eosinophils in allergic airways remodeling. Science305(5691), 1776–1779 (2004).
   PubMed Web of Science ®Google Scholar
• Mishra A, Hogan SP, Brandt EB, Rothenberg ME. An etiological role for aeroallergens and eosinophils in experimental esophagitis. J. Clin. Invest.107(1), 83–90 (2001).
   PubMed Web of Science ®Google Scholar
• Garlisi CG, Kung TT, Wang P et al. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am. J. Respir. Cell Mol. Biol.20(2), 248–255 (1999).
   PubMed Web of Science ®Google Scholar
• Leckie MJ, ten BA, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet356(9248), 2144–2148 (2000).
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med.167(2), 199–204 (2003).
   PubMed Web of Science ®Google Scholar
• Phipps S, Flood-Page P, Menzies-Gow A, Ong YE, Kay AB. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J. Invest. Dermatol.122(6), 1406–1412 (2004).
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med.176(11), 1062–1071 (2007).
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med.360(10), 973–984 (2009).
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med.360(10), 985–993 (2009).
   PubMed Web of Science ®Google Scholar
• Blanchard C, Wang N, Stringer KF et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J. Clin. Invest.116(2), 536–547 (2006).
   PubMed Web of Science ®Google Scholar
• Vicario M, Blanchard C, Stringer KF et al. Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis. Gut59(1), 12–20 (2010).
   PubMed Web of Science ®Google Scholar
• Abonia JP, Blanchard C, Butz BB et al. Involvement of mast cells in eosinophilic esophagitis. J. Allergy Clin. Immunol.126(1), 140–149 (2010).
   PubMed Web of Science ®Google Scholar
• Croese J, Fairley SK, Masson JW et al. Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest. Endosc.58(4), 516–522 (2003).
   PubMed Web of Science ®Google Scholar
• Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N. Engl. J. Med.351(9), 940–941 (2004).
   PubMed Web of Science ®Google Scholar
• Straumann A, Simon HU. Eosinophilic esophagitis: escalating epidemiology? J. Allergy Clin. Immunol.115(2), 418–419 (2005).
   PubMed Web of Science ®Google Scholar
• Gill R, Durst P, Rewalt M, Elitsur Y. Eosinophilic esophagitis disease in children from West Virginia: a review of the last decade (1995–2004). Am. J. Gastroenterol.102(10), 2281–2285 (2007).
   PubMedGoogle Scholar
• Kugathasan S, Judd RH, Hoffmann RG et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J. Pediatr.143(4), 525–531 (2003).
   PubMed Web of Science ®Google Scholar
• Turunen P, Kolho KL, Auvinen A, Iltanen S, Huhtala H, Ashorn M. Incidence of inflammatory bowel disease in Finnish children, 1987–2003. Inflamm. Bowel. Dis.12(8), 677–683 (2006).
   PubMed Web of Science ®Google Scholar
• Stein ML, Collins MH, Villanueva JM et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol.118(6), 1312–1319 (2006).
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Grzonka P et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut59(1), 21–30 (2010).
   PubMed Web of Science ®Google Scholar
• Aceves S, Gupta S, Justinich C et al. Clinical characteristics of pediatric eosinophilic esophagitis subjects with inadequate response to or intolerance of prior therapies receiving mepolizumab in a multicenter clinical trial. J. Allergy Clin. Immunol.125(2), AB159 (2010).
   Google Scholar
• Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am. J. Med.115(7), 587–589 (2003).
   PubMed Web of Science ®Google Scholar
• Plotz SG, Simon HU, Darsow U et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N. Engl. J. Med.349(24), 2334–2339 (2003).
   PubMed Web of Science ®Google Scholar
• Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk. Res.26(9), 881–884 (2002).
   PubMed Web of Science ®Google Scholar
• Cortes J, Ault P, Koller C et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood101(12), 4714–4716 (2003).
   PubMed Web of Science ®Google Scholar
• Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet359(9317), 1577–1578 (2002).
   PubMed Web of Science ®Google Scholar
• Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: current concepts and treatments. Br. J. Haematol.145(3), 271–285 (2009).
   PubMed Web of Science ®Google Scholar
• Garrett JK, Jameson SC, Thomson B et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J. Allergy Clin. Immunol.113(1), 115–119 (2004).
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med.358(12), 1215–1228 (2008).
   PubMed Web of Science ®Google Scholar
• Kahn JE, Grandpeix-Guyodo C, Marroun I et al. Sustained response to mepolizumab in refractory Churg–Strauss syndrome. J. Allergy Clin. Immunol.125(1), 267–270 (2010).
   PubMed Web of Science ®Google Scholar
• Sinico RA, Di TL, Maggiore U et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg–Strauss syndrome. Arthritis Rheum.52(9), 2926–2935 (2005).
   PubMed Web of Science ®Google Scholar
• Stein ML, Villanueva JM, Buckmeier BK et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J. Allergy Clin. Immunol.121(6), 1473–1483, 1483 (2008).
   PubMed Web of Science ®Google Scholar
• Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg–Strauss syndrome. J. Allergy Clin. Immunol.125(6), 1336–1343 (2010).
   PubMed Web of Science ®Google Scholar
• Oldhoff JM, Darsow U, Werfel T et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy60(5), 693–696 (2005).
   PubMed Web of Science ®Google Scholar
• Busse WW, Ring J, Huss-Marp J, Kahn JE. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J. Allergy Clin. Immunol.125(4), 803–813 (2010).
   PubMed Web of Science ®Google Scholar
• Klion AD, Bochner BS, Gleich GJ et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J. Allergy Clin. Immunol.117(6), 1292–1302 (2006).
   PubMed Web of Science ®Google Scholar
• Klion AD. Approach to the therapy of hypereosinophilic syndromes. Immunol. Allergy Clin. North Am.27(3), 551–560 (2007).
   PubMed Web of Science ®Google Scholar
• Baldini C, Talarico R, Della RA, Bombardieri S. Clinical manifestations and treatment of Churg–Strauss syndrome. Rheum. Dis. Clin. North Am.36(3), 527–543 (2010).
   PubMed Web of Science ®Google Scholar
• Gevaert P, Lang-Loidolt D, Lackner A et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J. Allergy Clin. Immunol.118(5), 1133–1141 (2006).
   PubMed Web of Science ®Google Scholar
• Gevaert P, Bruaene NV, Blomme K, Sousa AR, Marshal RP, Bachert C. Mepolizumab, A humanised anti-IL-5 monoclonal antibody, as treatment of severe nasal polyposis. J. Allergy Clin. Immunol.121(3), 797 (2008).
   Google Scholar